Wellthy Therapeutics and ManipalCigna collaborate to offer Proheal to its insured beneficiaries

The program will encourage the insured beneficiaries to adhere to on-going medications and treatments throughout their policy duration and avail discounts at renewal by following the program 

Mumbai, November 02nd 2020 (GPN): Wellthy therapeutics has collaborated with ManipalCigna, to present Proheal, a wellness program, to manage chronic illness and boost better health outcomes. The program can be availed by the existing as well as new policyholders of the Pro Health Insurance Plan 

Proheal is designed with an objective to boost medical monitoring and encourage adherence to ongoing medication, the two crucial aspects to handle chronic conditions. Covering a realm of chronic conditions including diabetes, hypertension, Cardiovascular Diseases, obesity, and Dyslipidemia, ProHeal aims at sensitizing the policyholders about the importance and the role of medication adherence in combating chronic conditions and reducing incidences of hospitalisations. The combination of digital therapeutics and insurance offers a holistic healthcare plan for the beneficiaries. The suggestions and advice would include important factors like monitoring daily diet, exercise regime, stress-management, sugar and HB levels, and more.   At the renewal of the policy, the reports and medical adherence followed by the beneficiary will be assessed and basis the comparison of desired and achieved outcome, a discount on the policy renewal will be considered. ENDS

About Wellthy Therapeutics 

Wellthy Therapeutics is a digital therapeutics (DTx) company that helps healthcare stakeholders to improve patient outcomes. Its digital therapeutics platform works to manage and improve complex clinical conditions, and works closely with pharma, med device, life insurers, health insurers and healthcare systems to achieve the same. 

Wellthy Therapeutics’ platform develops and deploys digital therapeutic candidates for commercialisation in indications across cardiology, nephrology and diabetes, and is live in two countries. The company has 20+ publications showcasing its real-world evidence. For more information, please visit www.wellthytherapeutics.com .